Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Kazuyoshi Imaizumi"'
Autor:
Toshikazu Watanabe, Takashi Hirama, Ken Onodera, Hirotsugu Notsuda, Hisashi Oishi, Hiromichi Niikawa, Kazuyoshi Imaizumi, Yoshinori Okada
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Interstitial lung disease (ILD) represents a heterogeneous group of lung disorders characterized by fibrotic lung tissue changes. In regions with severe donor shortages, single-lung transplantation (SLTx) is often preferred over b
Externí odkaz:
https://doaj.org/article/892534cc754c41a5aa095cac140a347e
Autor:
Takahiro Inoue, Sumito Isogai, Naoki Yamamoto, Noriko Hiramatsu, Yoshikazu Niwa, Hideaki Takahashi, Yutaro Kimura, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 18 (2024)
Background: Bronchial thermoplasty (BT) is a recently developed non-pharmacological therapy for refractory bronchial asthma. Although increasing evidence has suggested that BT is effective for various phenotypes of severe asthma, its safety and effic
Externí odkaz:
https://doaj.org/article/54999a9cac1c45368c01a538cc175826
Autor:
Reiko Matsuzawa, Masahiro Morise, Kentaro Ito, Osamu Hataji, Kosuke Takahashi, Junji Koyama, Yachiyo Kuwatsuka, Yasuhiro Goto, Kazuyoshi Imaizumi, Hidetoshi Itani, Teppei Yamaguchi, Yoshitaka Zenke, Masahide Oki, Makoto Ishii
Publikováno v:
EClinicalMedicine, Vol 66, Iss , Pp 102303- (2023)
Summary: Background: Immune checkpoint inhibitors (ICI) plus platinum-based chemotherapy has been recognized as a standard first-line therapy in non-small cell lung cancer (NSCLC); however, no prospective clinical trials of docetaxel (DTX) plus ramuc
Externí odkaz:
https://doaj.org/article/5bf2a2ed2cfa401eb7d3e4461978588a
Autor:
Masamichi Hayashi, Sayako Morikawa, Yusuke Goto, Takazumi Yoshida, Yutaro Kimura, Taku Kawabe, Seiichiro Tsuzuki, Kazuyoshi Imaizumi
Publikováno v:
Fujita Medical Journal, Vol 9, Iss 1, Pp 17-21 (2023)
Objectives: There are few reports about patients hospitalized for COVID-19 in Japan. We investigated 200 patients hospitalized for COVID-19 over a 6-month period with the aim of elucidating their clinical characteristics and clinical courses. Meth
Externí odkaz:
https://doaj.org/article/6c87266fd2c744469e87e46eee569406
Autor:
Toshiharu Sasaki, Yoko Toyama, Tomoya Horiguchi, Masaya Hibino, Sei-ichiro Tsuzuki, Masamichi Hayashi, Yohei Doi, Mitsunaga Iwata, Kazuyoshi Imaizumi, Masato Inaba
Publikováno v:
Fujita Medical Journal, Vol 9, Iss 1, Pp 30-34 (2023)
Objectives: Coronavirus disease 2019 (COVID-19) has affected nearly half million people in Japan. However, information on the prolonged symptoms as well as laboratory and radiographic findings after hospital discharge remains limited. Methods: We
Externí odkaz:
https://doaj.org/article/033ea02ee05d4c1fa4795a623d7ce18c
Autor:
Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100508- (2023)
Introduction: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan. Methods:
Externí odkaz:
https://doaj.org/article/bcbe60e4a4f34c35855ba34ee7b7698a
Autor:
Masamichi Hayashi, Sayako Morikawa, Yusuke Goto, Takazumi Yoshida, Yutaro Kimura, Kazuyoshi Imaizumi
Publikováno v:
Fujita Medical Journal, Vol 8, Iss 3, Pp 79-82 (2022)
Objectives: Various measures have been taken to curb the COVID-19 epidemic, but their effect has been limited. Vaccines are expected to make a definite improvement. In Japan, vaccination began in February 2021. However, there are very few reports of
Externí odkaz:
https://doaj.org/article/7ccff8cdbb22435db933acc8df840572
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Artificial intelligence (AI) applications in medical imaging continue facing the difficulty in collecting and using large datasets. One method proposed for solving this problem is data augmentation using fictitious images generated by genera
Externí odkaz:
https://doaj.org/article/2a7a29413eb44f12a4ae27ed9901d102
Autor:
Yuki Mieno, Masamichi Hayashi, Mariko Hirochi, Aki Ikeda, Hisashi Kako, Takuma Ina, Yuri Maeda, Shingo Maeda, Takahiro Inoue, Tomohide Souma, Toshikazu Watanabe, Tomoya Horiguchi, Yusuke Gotoh, Yoshikazu Niwa, Kumiko Yamatsuta, Sayako Morikawa, Yosuke Sakakibara, Takuya Okamura, Sakurako Uozu, Yasuhiro Goto, Sumito Isogai, Shiho Fujita, Junichi Fukumoto, Nami Hosoda, Kazuyoshi Imaizumi
Publikováno v:
Fujita Medical Journal, Vol 8, Iss 1, Pp 17-24 (2022)
Objective: The prevalence of obstructive sleep apnea (OSA) in Japan is 9% among males and 3% among females. Up to 2.5 million patients are estimated to suffer from the disease, but limited number of facilities are capable of carrying out polysomnogra
Externí odkaz:
https://doaj.org/article/1845003f10134ef899eccd6862c6b752
Autor:
Toshiyuki Yonezawa, Atsushi Suzuki, Kensuke Fukumitsu, Takuma Katano, Hisashi Kako, Makoto Ishii, Akio Niimi, Kazuyoshi Imaizumi, Koji Sakamoto, Norihito Omote, Etsuro Yamaguchi
Publikováno v:
Respiratory Medicine Case Reports, Vol 43, Iss , Pp 101857- (2023)
We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination thera
Externí odkaz:
https://doaj.org/article/c73b6b7c9ac94c4a87bb80cc1c4c5be1